Background The efficacy of coronavirus disease 2019 (COVID-19) convalescent plasma
(CCP) is primarily ascribed as a source of neutralizing anti-severe acute respiratory …

Abstract Coronavirus Disease 2019 (COVID-19) convalescent plasma (CCP) was approved
by the FDA for use in severe cases of COVID-19 under an emergency Investigational New …

Background Recent evidence suggested that the higher titers of anti-severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody from convalescent plasma …

Convalescent plasma (CP) have been used for treatment of coronavirus disease 2019
(COVID-19), but their effectiveness varies significantly. Moreover, the impact of CP treatment …

Background and objectives In the absence of a vaccine or specific drug treatment options for
coronavirus disease (COVID‐19), attention has been shifted in China to the possible …

Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but
the antibody characteristics that contribute to efficacy remain poorly understood. This study …

Background: Convalescent plasma is one of the treatment options for COVID-19 which is
currently being investigated in many clinical trials. Understanding of donor and product …

Background: Anti-SARS-CoV-2 virus antibody levels in convalescent plasma (CP), which
may be useful in severe Anti-SARS-CoV-2 virus infections, have been rarely reported …

Convalescent plasma (CP) has emerged as a treatment for COVID-19. However, the
composition and mechanism of action are not fully known. Therefore, we undertook a two …

Early COVID-19 convalescent plasma (CCP) transfusion to outpatients with COVID-19
decreases progression to hospitalization, but the mechanism of how CCP reduces severity …